author-photo

J.R. Hecht

University of California, Los Angeles

41

Papers

4761

Citations

Citation Trend

Filter By

Papers (31) Sort By

Journal Conference Others

Survival Advantage of Yttrium-90 Radioembolization to Systemic Therapy in Patients with Hepatic Metastases from Colorectal Cancer in the Salvage Setting: Results of a Matched Pair Study.

2021 Academic Radiology
Show All
- Source
- Cite
- Save
Citations (0)
CAUTION ADVISED USING COMBINATION KETOCONAZOLE AND PD-1 INHIBITORS.

2020 AACE clinical case reports
Show All
- Source
- Cite
- Save
Citations (1)
Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety

2019 Immunotherapy
Show All
- Source
- Cite
- Save
Citations (35)
744POverall survival and immunologic responses in metastatic pancreatic adenocarcinoma (PDAC) on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX)

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract PR08: Antitumor activity and immune correlates of PEGylated human IL-10 (AM0010) alone or in combination with anti-PD-1

2016 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (1)
PD-014First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC)

2015 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (71)
317 Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies

2015 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (3)
Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy

2015 Expert Review of Anticancer Therapy
Show All
- Source
- Cite
- Save
Citations (67)
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (409)